Evidence map›Paper›PMID 42539988›Full record

ArticleFundamental research2026

Chromatin regulator expression patterns predict prognosis and guide neoadjuvant therapy in esophageal squamous cell carcinoma.

Jia Liu, Wenyan Sun, Jiangcong Ma, Chengxiang Han, Qinghao Zhu, Yang Li, Shuwen Zheng, Xin Sun, Yong Huang, Qiong Wu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Fundamental research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jia LiuWest China Second University Hospital, Sichuan University, Chengdu 610041, China.
Wenyan SunKey Laboratory of Laboratory Medicine, Ministry of Education, Institute of Genomic Medicine, School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou 325035, China.
Jiangcong MaNational Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou 325041, China.
Chengxiang HanSchool of Life Science and Technology, Faculty of Life Sciences and Medicine, Harbin Institute of Technology, Harbin 150080, China.
Qinghao ZhuNational Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou 325041, China.
Yang LiNational Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou 325041, China.
Shuwen ZhengWest China Second University Hospital, Sichuan University, Chengdu 610041, China.
Xin SunWest China Hospital, Sichuan University, Chengdu 610041, China.
Yong HuangWest China Second University Hospital, Sichuan University, Chengdu 610041, China.
Qiong WuSchool of Life Science and Technology, Faculty of Life Sciences and Medicine, Harbin Institute of Technology, Harbin 150080, China.
Chenghao LiNational Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou 325041, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chromatin regulators (CRs), as key components of the epigenetic machinery, participate in tumor progression and therapeutic resistance by modulating chromatin structure and gene expression. Nonetheless, the precise functions of CRs in cancer immunotherapy and the tumor microenvironment (TME) remain largely unexplored. Here, we integrated multi-omics data to characterize genomic alterations, transcriptomic profiles, and copy number variations (CNVs) of 215 CRs and identified survival-associated CRs using Cox regression analysis. Subsequently, based on CR expression patterns, esophageal squamous cell carcinoma (ESCC) patients were classified into CR-active and CR-silent subgroups, which exhibited distinct survival outcomes and TME characteristics. Importantly, the CR-Score developed here was associated with treatment response-related endpoints and post-treatment disease-free survival in patients receiving neoadjuvant PD-1 blockade therapy. In summary, we systematically characterized the molecular and immune features of CR clusters in ESCC and demonstrated that the CR-Score is a novel biomarker for prognostic prediction, with potential clinical utility and theoretical relevance for neoadjuvant immunotherapy.

Indexed as

Chromatin regulatorsEsophageal squamous cell carcinomaImmunotherapyPrognostic biomarkerTumor microenvironment

Identifiers

PMID42539988
PMCPMC13424959

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.